Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up After Analyst Upgrade

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped up before the market opened on Monday after B Riley upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $8.37, but opened at $9.10. Capricor Therapeutics shares last traded at $8.8360, with a volume of 692,821 shares changing hands.

Other equities analysts have also issued reports about the company. Cantor Fitzgerald raised Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Friday, August 14th. Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Friday. JonesTrading lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Finally, Oppenheimer upgraded Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 25th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $30.25.

Insider Transactions at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 25,000 shares of company stock worth $759,158 over the last three months. 9.20% of the stock is currently owned by company insiders.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: B. Riley upgraded CAPR to “Buy” and set a $21 price target, implying substantial upside from the reference price of $8.37. The upgrade suggests the firm sees the recent selloff as excessive and believes Capricor’s pipeline could recover value. Briefing.com analyst upgrade
• Neutral Sentiment: Capricor remains a high-risk, binary biotechnology investment. A recent market overview identified the company as having pivotal clinical or regulatory catalysts before the end of 2026. Results from these events could materially change expectations for the company’s lead programs and cause significant volatility. MarketBeat article on small-cap biotech catalysts
• Negative Sentiment: Several law firms are promoting a securities class action against Capricor and certain executives. The lawsuit covers investors who purchased shares between December 17, 2025, and July 26, 2026, and alleges securities-law violations connected to clinical-data disclosures and a significant stock decline. Investors have until September 28, 2026, to seek appointment as lead plaintiff. The notices are largely repetitive and do not establish wrongdoing, but they add legal overhang, potential costs and reputational risk. Kaplan Fox class action announcement

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CAPR. Royal Bank of Canada boosted its holdings in shares of Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. KBC Group NV purchased a new position in shares of Capricor Therapeutics during the 1st quarter valued at about $44,000. ACT Capital Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter worth approximately $43,000. Nuveen LLC boosted its stake in Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after buying an additional 1,878 shares in the last quarter. Finally, State of Wyoming grew its position in Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Up 5.6%

The firm has a market capitalization of $513.67 million, a P/E ratio of -3.60 and a beta of 0.72. The business’s 50-day simple moving average is $11.05 and its 200 day simple moving average is $23.18.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.